Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil

Ferreira, Vinicius Lins; Borba, Helena Hiemisch Lobo; Wiens, Astrid; Pedroso, Maria Lucia Alves; Radunz, Vanessa Ferreira de Camargo; Ivantes, Cláudia Alexandra Pontes; Kuniyoshi, Aline Satie Oba; Pontarolo, Roberto.
Braz. j. infect. dis ; 22(3): 186-192, May-June 2018. tab, graf
Artículo en Inglés | LILACS | ID: biblio-974205

Documentos relacionados

  1. Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil.
  2. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
  3. Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases.
  4. Simeprevir and sofosbuvir for treatment of hepatitis C infection.
  5. Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.
  6. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
  7. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.
  8. Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus.
  9. Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon.
  10. A novel fixed-dose combination treatment for chronic hepatitis C, based on NS5A inhibitor fopitasvir and NS5B inhibitor sofosbuvir.